- Home
- DVAX vs DCOMP Comparison
DVAX vs DCOMP Comparison
Compare DVAX & DCOMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- DCOMP
- Stock Information
- Founded
- DVAX 1996
- DCOMP N/A
- Country
- DVAX United States
- DCOMP United States
- Employees
- DVAX N/A
- DCOMP 887
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- DCOMP Major Banks
- Sector
- DVAX Health Care
- DCOMP Finance
- Exchange
- DVAX Nasdaq
- DCOMP Nasdaq
- Market Cap
- DVAX 1.3B
- DCOMP N/A
- IPO Year
- DVAX 2004
- DCOMP N/A
- Fundamental
- Price
- DVAX $9.57
- DCOMP $20.21
- Analyst Decision
- DVAX Buy
- DCOMP
- Analyst Count
- DVAX 4
- DCOMP 0
- Target Price
- DVAX $26.50
- DCOMP N/A
- AVG Volume (30 Days)
- DVAX 2.0M
- DCOMP N/A
- Earning Date
- DVAX 11-06-2025
- DCOMP N/A
- Dividend Yield
- DVAX N/A
- DCOMP N/A
- EPS Growth
- DVAX N/A
- DCOMP N/A
- EPS
- DVAX N/A
- DCOMP N/A
- Revenue
- DVAX $316,268,000.00
- DCOMP N/A
- Revenue This Year
- DVAX $23.23
- DCOMP N/A
- Revenue Next Year
- DVAX $16.57
- DCOMP N/A
- P/E Ratio
- DVAX N/A
- DCOMP N/A
- Revenue Growth
- DVAX 26.66
- DCOMP N/A
- 52 Week Low
- DVAX $9.20
- DCOMP N/A
- 52 Week High
- DVAX $14.63
- DCOMP N/A
- Technical
- Relative Strength Index (RSI)
- DVAX 39.47
- DCOMP 67.25
- Support Level
- DVAX $9.20
- DCOMP $19.96
- Resistance Level
- DVAX $9.94
- DCOMP $20.32
- Average True Range (ATR)
- DVAX 0.30
- DCOMP 0.30
- MACD
- DVAX -0.04
- DCOMP 0.10
- Stochastic Oscillator
- DVAX 31.90
- DCOMP 95.65
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About DCOMP Dime Community Bancshares Inc. Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series A
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.